I S A B E L L A TA P I L AT U , S . K E D .
M A E D I E L M PA B A S S I N G , S . K E D .
NURFITRIA, S.KED.
PA U L I N A N W E YA I , S . K E D .
PENGUJI :
DR. I M M A C U L ATA P U R WA N I N G S I H ,
S P. A .
2
Abstract
Acute diarrhoea is a leading cause of morbidity and mortality in the paediatric
population. Racecadotril is an antisecretory drug recommended as an adjuvant anti-
diarrhoeal treatment. In the small bowel, the enzyme neutral endopeptidase (NEP)
inhibits the action of enkephalins, which prevent water and electrolyte hypersecretion. By
inhibiting NEP, racecadotril allows enkephalins to exhibit their antisecretory effects.
Consequently, racecadotril reduces the secretion of water and electrolytes in the small
intestine, without having an effect on intestinal motility. No serious adverse events
related to racecadotril have been reported. Racecadotril has proven its efficacy as an
adjuvant anti-diarrhoeal drug with a good safety profile. Its addition to oral rehydration
solution (ORS) appears clinically beneficial and potentially leads to health care savings.
Key Words: racecadotril, adjuvant, gastroenteritis
POIN PEMBELAJARAN 3
3. urtikaria,
4. eritem multiforme,
6. edema angioneurotik
KONTRAINDIKASI & INTERAKSI 17
TERIMA KASIH